- Home
- CATO vs GANX Comparison
CATO vs GANX Comparison
Compare CATO & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATO
- GANX
- Stock Information
- Founded
- CATO 1946
- GANX 2017
- Country
- CATO United States
- GANX United States
- Employees
- CATO N/A
- GANX N/A
- Industry
- CATO Clothing/Shoe/Accessory Stores
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- CATO Consumer Discretionary
- GANX Health Care
- Exchange
- CATO Nasdaq
- GANX Nasdaq
- Market Cap
- CATO 59.2M
- GANX 53.8M
- IPO Year
- CATO N/A
- GANX 2021
- Fundamental
- Price
- CATO $2.87
- GANX $1.64
- Analyst Decision
- CATO
- GANX Strong Buy
- Analyst Count
- CATO 0
- GANX 5
- Target Price
- CATO N/A
- GANX $8.20
- AVG Volume (30 Days)
- CATO 43.0K
- GANX 316.1K
- Earning Date
- CATO 08-21-2025
- GANX 08-07-2025
- Dividend Yield
- CATO 6.11%
- GANX N/A
- EPS Growth
- CATO N/A
- GANX N/A
- EPS
- CATO N/A
- GANX N/A
- Revenue
- CATO $642,949,000.00
- GANX N/A
- Revenue This Year
- CATO N/A
- GANX N/A
- Revenue Next Year
- CATO N/A
- GANX N/A
- P/E Ratio
- CATO N/A
- GANX N/A
- Revenue Growth
- CATO N/A
- GANX N/A
- 52 Week Low
- CATO $2.19
- GANX $0.89
- 52 Week High
- CATO $6.70
- GANX $3.19
- Technical
- Relative Strength Index (RSI)
- CATO 53.03
- GANX 40.97
- Support Level
- CATO $2.73
- GANX $1.65
- Resistance Level
- CATO $2.99
- GANX $2.04
- Average True Range (ATR)
- CATO 0.18
- GANX 0.16
- MACD
- CATO -0.02
- GANX -0.01
- Stochastic Oscillator
- CATO 30.14
- GANX 17.21
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.